Ensol Biosciences Inc
140610
Company Profile
Business description
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.
Contact
51, Techno 10-ro
Yuseong-gu
Daejeon34036
KORT: +82 429394500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.40 | 51.20 | 0.57% |
| CAC 40 | 7,696.85 | 22.86 | -0.30% |
| DAX 40 | 23,707.66 | 112.86 | 0.48% |
| Dow JONES (US) | 45,271.23 | 24.58 | -0.05% |
| FTSE 100 | 9,193.67 | 15.68 | 0.17% |
| HKSE | 25,058.51 | 284.92 | -1.12% |
| NASDAQ | 21,497.73 | 218.10 | 1.02% |
| Nikkei 225 | 42,580.27 | 641.38 | 1.53% |
| NZX 50 Index | 13,133.20 | 58.39 | 0.45% |
| S&P 500 | 6,448.26 | 32.72 | 0.51% |
| S&P/ASX 200 | 8,826.50 | 59.20 | 0.68% |
| SSE Composite Index | 3,765.88 | 47.68 | -1.25% |